COPENHAGEN, Denmark, November 13, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) publishes corrected information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Anu Helena Kerns | |
| 2. | Reason for the notification | ||
| a) | Position/status
|
Executive Vice President People & Organization of Bavarian Nordic A/S | |
| b) | Initial notification/Amendment | Amendment to notification of November 11, 2020. The volume of granted warrants has been adjusted. | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Bavarian Nordic A/S | |
| b) | LEI | 2138006JCDVYIN6INP51 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument
Identification code |
Warrants
DK0015998017 |
|
| b) | Nature of the transaction | Grant | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 0.00 | 38,756 | ||
| d) | Aggregated information
|
38,756 |
|
| e) | Date of the transaction | 2020-11-11 | |
| f) | Place of the transaction | Outside a trading venue | |
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit www.bavarian-nordic.com.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 49 / 2020
Attachment
MIAMI, FL / ACCESS Newswire / January 8, 2026 / What began as a visionary…
HOUSTON, Jan. 8, 2026 /PRNewswire/ -- Bionova Scientific LLC, an Asahi Kasei company and a…
Company unifies its AI ecosystem under doceree.ai, launches five industry-first AI solutions, earns top global…
SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- Livelong Media is proud to announce Dr. Mark…
CHATTANOOGA, Tenn., Jan. 8, 2026 /PRNewswire/ -- Cleanova, a leading global manufacturer of advanced industrial filtration…
SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- The life sciences industry is buzzing about AI's…